Evidence map›Paper›PMID 42948374›Full record

ReviewActa pharmaceutica Sinica. B2026

Molecular mechanisms, crosstalk and therapeutic potential of novel acylation modifications in cardiovascular and cerebrovascular diseases.

Wanchun Li, Weile Ye, Jiaojiao Wang, Zhiping Liu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Acta pharmaceutica Sinica. B, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Wanchun LiState Key Laboratory of Bioactive Molecules and Druggability Assessment/Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs/Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research/International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Ministry of Education (MOE) of China/College of Pharmacy, Jinan University, Guangzhou 511436, China.
Weile YeState Key Laboratory of Bioactive Molecules and Druggability Assessment/Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs/Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research/International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Ministry of Education (MOE) of China/College of Pharmacy, Jinan University, Guangzhou 511436, China.
Jiaojiao WangSchool of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, China.
Zhiping LiuState Key Laboratory of Bioactive Molecules and Druggability Assessment/Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs/Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research/International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Ministry of Education (MOE) of China/College of Pharmacy, Jinan University, Guangzhou 511436, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metabolic reprogramming, the fundamental process by which cells adapt to fluctuations in energy demands, is pivotal in the pathophysiology of cardiovascular and cerebrovascular diseases (CCVDs). Aberrant reprogramming of glucose, lipid, and amino acid metabolism is intricately associated with pathological processes in CCVDs such as cardiac hypertrophy, atherosclerosis, and ischemia-reperfusion injury. This metabolic remodeling disrupts the dynamic balance of metabolites (cc, acetyl-CoA and lactate) in the cardio-cerebrovascular systems, thereby inducing abnormal post-translational modifications (PTMs) on histones and non-histone proteins. These PTMs drive disease progression by modulating gene transcription or the activity of key proteins, which subsequently influences downstream signaling pathways. Here, we systematically examine the regulatory enzymes and functional roles of nine recently characterized acylation modifications: crotonylation,

Indexed as

Acetyl-CoAAcylation modificationsCardiovascular diseaseCerebrovascular diseaseEpigeneticsLactylationMetabolic reprogrammingPost-translational modifications

Identifiers

PMID42948374
PMCPMC13712274

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.